&w=3840&q=100)
Glenmark Pharma launches lung cancer treatment drug Tevimbra in India
Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation.
Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing.
"At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact," Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said.
Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients".
Tevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophagal squamous cell carcinoma (ESCC) as monotherapy, the company said.
It is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
33 minutes ago
- Time of India
Hope for AML patients with rare gene mutation
Pune: New and emerging therapies, which cause less collateral damage to normal blood and target specific mutations, are a promising alternative to treat Acute Myeloid Leukemia (AML), several oncologists have said. June is AML awareness month. Specialists have begun using ivosidenib, one such drug, that targets AML with IDH mutation, after Central Drugs Standard Control Organisation approved it in May. You Can Also Check: Pune AQI | Weather in Pune | Bank Holidays in Pune | Public Holidays in Pune India accounts for the highest number of AML cases after the US and China as per statistics from 2021. Dr Sameer Melinkeri, clinical haematologist at Pune's Deenanath Mangeshkar Hospital & Research Centre, said new therapies such as ivosidenib, azacitidine and venetoclax, help precisely target individual mutations in AML. "Ivosidenib is the first targeted therapy developed specifically for AML patients who carry the rare IDH1 gene mutation," said Dr Melinkeri. "It blocks a faulty enzyme—mutant IDH1—that causes the buildup of a harmful substance called 2-hydroxyglutarate in the body. This substance stops blood cells from maturing and spreads cancer cells," the doctor added. He said ivosidenib turns off the cancer-causing switch (mutation) in patients with IDH, a specific gene mutation. By stopping the enzyme, ivosidenib helps blood cells mature normally, reducing cancerous cells and allowing healthy cells to grow. Dr Reshma Puranik, a medical and haemato-oncologist with MOC, Cancer Care and Research Centre said that ivosidenib is a first-in-class, oral, small-molecule inhibitor of the mutant IDH1 enzyme and works well in brain tumors with IDH mutation. In trials, ivosidenib and azacitidine achieved superior outcomes with similar toxicity compared to azacitidine with newly-diagnosed IDH1-mutated AML. "Patients on ivosidenib need to monitor blood counts along with renal and liver function tests, serum electrolytes and QT interval on ECG. Some patients get a minor rash, feel fatigued, have oral mucositis (ulcers) and are at risk of differentiation syndrome," Dr Puranik added. While the new targeted therapies are expensive, more awareness and distributors in the market will bring the cost down, experts say. Dr Shilpa Gupta, consultant haemato-oncologist in a Mumbai-based cancer centre, said, "I have started ivosidenib for a patient and will wait for the results."
&w=3840&q=100)
Business Standard
12 hours ago
- Business Standard
Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra
Glenmark Pharmaceuticals share price today: Pharmaceutical major Glenmark Pharmaceuticals shares rose as much as 2.74 per cent to hit an intraday high of ₹1,728 per share on Wednesday, June 25, 2025. Around 1:05 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 1.82 per cent at ₹1,712.50 per share. In comparison, BSE Sensex was trading 0.71 per cent higher at 82,636.70 levels. Why did Glenmark Pharmaceuticals share price rise today? Glenmark Pharmaceuticals share price gained in trade after the company announced the launch of Tevimbra (tislelizumab) in India, following approval by the Central Drugs Standard Control Organisation (CDSCO). Tevimbra is a uniquely engineered anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology innovator focused on delivering cutting-edge cancer therapies. The drug is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy, and as a second-line monotherapy for both locally advanced/metastatic NSCLC and esophageal squamous cell carcinoma (ESCC). The launch marks Glenmark Pharmaceuticals' entry into the immuno-oncology space in India and is a key step in broadening its oncology portfolio with innovative therapies. NSCLC accounts for over 80 per cent of all lung cancer cases, while ESCC is the most prevalent histological subtype of esophageal cancer in India. Tevimbra addresses the major treatment needs of this large patient base with a differentiated and evidence-backed option, the company said. Already approved and available in major markets including the US, EU, Australia, and China, Tevimbra is designed to selectively bind to PD-1 receptors, restoring T-cell function and limiting off-target immune suppression. It has shown strong efficacy and a favourable safety profile across various solid tumors in multiple Phase 3 studies and a global clinical programme. Glenamark Pharmaceuticals Q4 results For the fourth quarter of FY2024-25 (Q4FY25), Glenmark Pharmaceuticals reported a consolidated revenue of ₹3,256.2 crore, marking a year-on-year (Y-o-Y) growth of 6.3 per cent from ₹3,063 crore in the same period last year. The company's Ebitda for the quarter stood at ₹560.7 crore, up 11.2 per cent from ₹504.3 crore, with an Ebitda margin of 17.2 per cent. Adjusted Profit After Tax (PAT) for the quarter came in at ₹346.6 crore, reflecting an adjusted PAT margin of 10.6 per cent. For the full fiscal year ended March 31, 2025 (FY25), the company's consolidated revenue rose 12.8 per cent to ₹13,321.7 crore, compared to ₹11,813.1 crore in the previous year. Ebitda for FY25 more than doubled to ₹2,351 crore from ₹1,195.3 crore, with the Ebitda margin improving to 17.6 per cent. The company also posted an adjusted PAT of ₹1,389.4 crore for the year, resulting in an adjusted PAT margin of 10.4 per cent. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-driven global pharmaceutical company with a strong presence across Branded, Generics, and OTC segments. The company focuses on key therapeutic areas including respiratory, dermatology, and oncology. With 11 state-of-the-art manufacturing facilities spread across four continents and operations in over 80 countries, Glenmark Pharmaceuticals has established itself as a major player in the global pharmaceutical landscape. The market capitalisation of Glenmark Pharmaceuticals is ₹48,171.68 crore, according to BSE. The company falls under the BSE 500 index. Glenmark Pharmaceuticals' 52-week high is ₹1,830.05 per share, while its 52-week low is ₹1,199.95 apiece.
&w=3840&q=100)
Business Standard
17 hours ago
- Business Standard
Stocks to Watch today: Union Bank, Hindalco, Vi, JB Chemicals, TaMo, Rites
Stocks to Watch Today, Wednesday, June 25, 2025: Indian equity markets are set to extend their positive momentum as the fragile truce between Iran and Israel appears to hold. Tensions in West Asia were under control after US President Donald Trump criticised both nations for breaching ceasefire agreements, just hours after they were agreed upon. That said, the early indicator of Nifty50 performance -- GIFT NIFTY -- was up 109 points or 0.44 per cent at 25,181 as of 7:50 AM. Track LIVE Updates Here Stock markets in Asia edged higher, taking cues from a strong close on Wall Street. Last checked, Japan's Nikkei was higher by 0.16 per cent, and South Korea's Kospi was up 0.3 per cent. Meanwhile, equities in the US were buoyed by easing tensions in West Asia, along with comments on potential rate cuts from Federal Reserve Chair Jerome Powell. Lower inflation and weaker labour hiring could lead to an earlier rate cut, Powell said, while the impact of trade tariffs has to be weighed. The S&P 500 index rose by 1.11 per cent, while the Dow Jones Industrial Average closed 1.19 per cent higher. Back home, on Tuesday, the BSE Sensex settled 158.32 points or 0.19 per cent higher at 82,055.11, while the Nifty50 rose 72.45 points or 0.29 per cent to end at 25,044.35. FIIs sold shares worth ₹5,266.01 crore, while DIIs net bought equities worth ₹5,209.6 crore. Meanwhile, below are some stocks to watch during today's session: Union Bank of India: The government has cancelled the appointment of Pankaj Dwivedi, one of the executive directors of the state-owned lender. Dwivedi, who was a general manager in Punjab & Sind Bank, was appointed as executive director of Union Bank in March last year, for a period of three years. Hindalco Industries: The Aditya Birla Group company announced the acquisition of a 100 per cent equity stake in US-based AluChem for $125 million. The deal will be executed through Aditya Holdings LLC, a step-down wholly owned subsidiary of Hindalco. The acquisition is expected to close in the next quarter. Vodafone Idea: The company said that it has not received any official communication from the government regarding relief on its ₹84,000 crore adjusted gross revenue (AGR) dues, despite reports suggesting that such relief is under consideration. Tata Motors: The auto major said that export restrictions on rare-earth magnets imposed by China have not yet disrupted its production pipeline, and the company is actively exploring alternate sources and technologies. Glenmark Pharmaceuticals: The pharma major said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. Aurobindo Pharma: The firm's subsidiary CuraTeQ Biologics received UK MHRA approval for Dyrupeg, its third biosimilar nod after Bevqolva and Zefylti, following earlier EU clearance in April 2025. JB Chemicals & Pharmaceuticals: The pharma company received US Food and Drug Administration (USFDA) approval for its ANDA of Amitriptyline Hydrochloride Tablets (10–150 mg), a generic antidepressant indicated for the relief of depression symptoms. BLS E-Services: The company, via subsidiary Zero Mass, signed a definitive agreement to acquire SBI and HDFC Bank Customer Service Points (CSPs) on a slump sale basis for ₹6.5 crore. This is to expand financial inclusion and enhance last-mile banking service delivery across India Himadri Speciality Chemical: The firm's board approved the acquisition of a 16.24 per cent stake in US-based International Battery Company for $4.43 million, comprising stock purchase from an existing shareholder and subscription to common and preferred shares. Rites: The company received a Letter of Intent (LoI) from Gujarat Urban Development Company for a ₹28.5 crore contract to serve as TPI agency for WSS/UGD/STP projects under Amrut 2.0/SJMMSVY over 60 months. Zydus Wellness: The company's board approved the voluntary liquidation of its subsidiary Naturell (India) Private Limited and cleared its consolidation with the parent entity to simplify the structure and drive synergies and operational efficiencies. PTC Industries: The company's subsidiary, Aerolloy Technologies Limited (ATL) and Safran Aircraft Engines inked a Memorandum of Understanding (MoU) to develop cooperation on the manufacturing of components and materials for military aircraft engines.
